Immune Checkpoint Inhibitor: An Emerging Treatment for Head and Neck Cancer. A Primer for the Radiologist
Learning Objectives: To recognize the emerging role, basic mechanism, and unique treatment response patterns of immune checkpoint inhibitors for the treatment of head and neck cancer, and to describe imaging findings of immune-related adverse events of immune checkpoint inhibitors.
Keywords: 89Zr = zirconium-89; CTLA-4 = cytotoxic T-lymphocyte‐associated antigen 4; HNSCC = head and neck squamous cell carcinoma; ICI = immune checkpoint inhibitor; NAE = neurologic adverse event; PD-L1 and PD-L2 = programmed cell death ligand 1 and 2; RECIST = Response Evaluation Criteria in Solid Tumors; anti‐PD-L1. Hyperprogression = programmed cell death protein 1; irAE = immune-related adverse event; irRC = immune-related response criteria
Document Type: Research Article
Publication date: October 1, 2020
Neurographics is the peer-reviewed, bimonthly educational journal of the American Society of Neuroradiology. The journal comprises articles selected from material presented at the ASNR Annual Meeting. Neurographics also publishes other high-quality submissions that are primarily educational and have a high emphasis on a pictorial approach. Neurographics offers CME credit for reading review articles and completing quiz-based self-assessment activities.
Visit the ASNR Education Connection to view all available CME courses.
- Editorial Board
- Information for Authors
- Membership Information
- Order a Print Copy
- Ingenta Connect is not responsible for the content or availability of external websites